Anzeige
Mehr »
Login
Donnerstag, 07.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
425 Leser
Artikel bewerten:
(2)

Stem Cells Market Size Worth $18.4 Billion By 2028 | CAGR: 8.8%: Grand View Research, Inc.

SAN FRANCISCO, March 9, 2021 /PRNewswire/ -- The global stem cells market size is expected to reach USD 18.4 billion by 2028, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.8% from 2021 to 2028. The market is driven by the rising number of stem cell banks, growing focus on increasing therapeutic potential of these, and extensive research for the development of regenerative medicines, among other factors.

GVR logo

Key suggestions from the report:

  • ASCs segment accounted for the largest share of 85.7% in 2020 as it is considered as a gold standard in stem cell-based therapies. They are widely accepted owing to their consistent clinical success especially in hematopoietic transplants and there is a relatively less controversial view regarding their origin
  • he iPSC segment is expected to witness a lucrative CAGR of 9.3% through 2021-2028 owing to the increasing focus of companies in using iPS for cell therapies. For instance, in July 2020, Cynata Therapeutics Limited announced positive results for the phase 1 clinical trial of CYP-001, the company's lead induced pluripotent stem cell (iPSC)-derived Cymerus
  • Regenerative medicine dominated with a market share of 89.1% in 2020 owing to increasing funding by the government for the development of regenerative medicines. For instance, in October 2020, the AusBiotech-led consortium received funding of $300,000 from MTPConnect's Industry Growth Centre Project Fund for the development of regenerative medicines in the country
  • Cell acquisition held the largest market share of 35.8% in 2020 and is expected to expand at the fastest CAGR through 2021-2028 owing to increasing research studies involving cell harvesting
  • Allogenic therapy dominated with a market share of 58.2% in 2020 owing to the increasing application of allogeneic stem cell transplants for cancer treatment
  • The North America market encompasses U.S. and Canada. The factors contributing to the market growth in the region include robust government funding, increasing research, and the presence of prominent players.
  • Asia Pacific is expected to expand with the fastest CAGR of 9.0% through 2021 to 2028 owing to increasing expansion by key companies in this region. For instance, in April 2020, Seneca Biopharma completed its new stem cell manufacturing facility in Suzhou, China

Read 150 page research report with ToC on "Stem Cells Market Size, Share & Trends Analysis Report By Product (Mesenchymal, Adult, iPSCs), By Application, By Technology (Cell Acquisition, Cryopreservation), By Therapy, By Region, And Segment Forecasts, 2021 - 2028" at: https://www.grandviewresearch.com/industry-analysis/stem-cells-market

Companies are receiving robust funding for the development of cellular therapies for cancer, which is anticipated to supplement the market growth. For instance, in February 2021, Notch Therapeutics, Inc. received funding of USD 85 million for developing induced pluripotent therapies for cancer. The investment will support the development of the company's iPSC-derived T cell-based therapeutic candidates and expanding the application of their proprietary Engineered Thymic Niche (ETN) platform.

The increasing focus on regenerative medicines is further driving the market growth. The iPSCs are gaining popularity for the development of personalized cellular therapies and are creating new opportunities for regenerative medicine. For instance, in September 2020, researchers from Duke-NUS and Monash University discovered the first stem cell that can help in the treatment of placenta complications during pregnancy.

The researchers discovered a new way for creating induced trophoblast stem cells which can be used for making placenta cells. The discovery will facilitate in developing a model human placenta in vitro and enabling a pathway for future cell therapies. The administration of cell therapy demonstrated positive results in the treatment of COVID-19 patients, which is further contributing to the market growth. In January 2020, a group of researchers used stem cell treatment on patients in Beijing, China for checking its effectiveness against COVID-19.

The patients received a single infusion of mesenchymal stem cells (MSCs) which was found to be effective in developing an immune response. However, to date, there are no MSCs that are approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 owing to insufficient data on their role in treating COVID-19.

Grand View Research has segmented the global stem cells market on the basis of product, application, technology, therapy, and region:

  • Stem Cells Product Outlook (Revenue, USD Million, 2017 - 2028)
    • Adult Stem Cells (ASCs)
      • Hematopoietic
      • Mesenchymal
      • Neural
      • Epithelial/Skin
      • Others
    • Human Embryonic Stem Cells (HESCs)
    • Induced Pluripotent Stem Cells (iPSCs)
    • Very Small Embryonic Like Stem Cells
  • Stem Cells Application Outlook (Revenue, USD Million, 2017 - 2028)
    • Regenerative Medicine
      • Neurology
      • Orthopedics
      • Oncology
      • Hematology
      • Cardiovascular and Myocardial Infraction
      • Injuries
      • Diabetes
      • Liver Disorder
      • Incontinence
      • Others
    • Drug Discovery and Development
  • Stem Cells Technology Outlook (Revenue, USD Million, 2017 - 2028)
    • Cell Acquisition
      • Bone Marrow Harvest
      • Umbilical Blood Cord
      • Apheresis
    • Cell Production
      • Therapeutic Cloning
      • In-vitro Fertilization
      • Cell Culture
      • Isolation
    • Cryopreservation
    • Expansion and Sub-Culture
  • Stem Cells Therapy Outlook (Revenue, USD Million, 2017 - 2028)
    • Autologous
    • Allogenic
  • Stem Cells Regional Outlook (Revenue, USD Million, 2017 - 2028)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Spain
      • Italy
    • Asia Pacific
      • China
      • Japan
      • India
    • Latin America
      • Brazil
      • Mexico
    • Middle East & Africa
      • South Africa
      • Saudi Arabia

List of Key Players of Stem Cells Market

  • CELGENE CORPORATION
  • STEMCELL Technologies Inc.
  • Lineage Cell Therapeutics, Inc.
  • Osiris Therapeutics, Inc.
  • Human Longevity, Inc.
  • Cynata
  • Cytori Therapeutics Inc.
  • Advanced Cell Technology Inc.
  • Promethera Biosciences
  • Mesoblast Ltd

Find more research reports onBiotechnology Industry, by Grand View Research:

  • Cell Culture Market - The global cell culture market size was estimated at USD 16.4 billion in 2014. Development of novel three-dimensional cell culture techniques and growing need for these techniques for biopharmaceutical development and vaccine production are expected to drive demand and growth in revenue.
  • Human Embryonic Stem Cells Market - The global human embryonic stem cells market size was valued at USD 494.7 million in 2015. These are the pluripotent cells that possess the ability to get differentiated into all germ layers. Rising demand owing to the increasing incidence of genetic disorders is anticipated to boost growth.
  • In-vitro Fertilization Market - The global in-vitro fertilization market size was estimated at USD 14.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 6.5% from 2021 to 2028. Key factors that are driving the market include rising reprotourism and the increasing incidence rate of male and female infertility.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:

Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

© 2021 PR Newswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.